StreetInsider.com News Articles

Form 6-K ALTERITY THERAPEUTICS For: Oct 31

Fri, 23 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261023/27224642.html

Form 6-K ALTERITY THERAPEUTICS For: Oct 31

Fri, 23 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261023/27224631.html

Form 6-K ALTERITY THERAPEUTICS For: Oct 31

Fri, 23 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261023/27224625.html

Form 6-K ALTERITY THERAPEUTICS For: Oct 31

Wed, 21 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261021/27212522.html

Form 6-K ALTERITY THERAPEUTICS For: Oct 31

Wed, 21 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261021/27212502.html

Form 6-K ALTERITY THERAPEUTICS For: Oct 31

Mon, 19 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261019/27200207.html

Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference

Fri, 09 Oct 2026 07:05:00 -0400

MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia.

At the conference, Dr. Stamler will deliver a corporate presentation and will also host roundtable discussions with investors.

About Alterity Therapeutics Limited

Alterity Therapeutics is a

Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference

Fri, 09 Oct 2026 07:05:00 -0400

At the conference, Dr. Stamler will deliver a corporate presentation and will also host roundtable discussions with investors.

About Alterity Therapeutics Limited

Alterity Therapeutics is a

Form 6-K ALTERITY THERAPEUTICS For: Oct 31

Fri, 09 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261009/27168780.html

Form 6-K ALTERITY THERAPEUTICS For: Oct 31

Mon, 05 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261005/27145116.html

Lake Street Starts Alterity Therapeutics (ATHE) at Buy

Tue, 15 Sep 2026 07:37:12 -0400

Lake Street analyst Thomas Flaten initiates coverage on Alterity Therapeutics (NASDAQ: ATHE) with a Buy rating and a price target of $10.00.

For an analyst ratings summary and ratings history on Alterity Therapeutics click here. For more ratings news on Alterity Therapeutics click here.

Shares of Alterity Therapeutics closed at $3.86 yesterday.

Craig-Hallum Starts Alterity Therapeutics (ATHE) at Buy

Tue, 11 Aug 2026 09:18:15 -0400

(Updated - August 11, 2026 9:18 AM EDT)

Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ: ATHE) with a Buy rating and a price target of $12.00.

The analyst comments "We view ATH434 as a high-risk but unusually asymmetric multiple system atrophy (MSA) pivotal story with substantial upside if Ph3 confirms the Ph2 signal. ATHE's current valuation appears to reflect financing, replication, and small-company execution risk while assigning limited value to an oral asset with randomized 12-mo functional data and a written FDA-confirmed registrational path. At current levels, the thesis does not require ATH434 to be de-risked; it requires recognizing

Craig-Hallum Starts Alterity Therapeutics (ATHE) at Buy

Tue, 11 Aug 2026 09:18:15 -0400

(Updated - August 11, 2026 9:18 AM EDT)

Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ: ATHE) with a Buy rating and a price target of $12.00.

Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update